This inventor holds 2 USPTO granted patents, plus 4 CIPO patents and 1 EPO patent. Top assignees: Dso National Laboratories, National University of Singapore. Active years: 2016-2019.
Company Filing History:
2 out of 14 
2 out of 850 
Years Active: 2016-2019
Title: En Wei Teo: Innovator in Dengue Virus Research
Introduction
En Wei Teo is a prominent inventor based in Singapore, known for his significant contributions to the field of medical research, particularly in the area of dengue virus treatment. With a total of 2 patents, his work focuses on developing human monoclonal antibodies that target the dengue virus, showcasing his commitment to advancing healthcare solutions.
Latest Patents
Teo's latest patents include a groundbreaking invention titled "Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof." This patent outlines compositions and methods for the treatment or prevention of dengue virus infection in vertebrate subjects. Specifically, it discloses human neutralizing monoclonal antibodies isolated from EBV immortalized B cells derived from patients who have recovered from dengue infection. The methods provided aim to administer these antibodies effectively to reduce, eliminate, or prevent relapse from infection.
Career Highlights
Throughout his career, En Wei Teo has worked with esteemed institutions such as the National University of Singapore and DSO National Laboratories. His research has significantly impacted the understanding and treatment of dengue virus infections, positioning him as a key figure in this vital area of study.
Collaborations
Teo has collaborated with notable colleagues, including Paul Macary and Ee Ping Evelyn Teoh, contributing to a rich environment of innovation and research.
Conclusion
En Wei Teo's work exemplifies the spirit of innovation in medical research, particularly in combating dengue virus infections. His patents and collaborations reflect a dedication to improving health outcomes and advancing scientific knowledge.